Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 11;15(6):766-777.
doi: 10.3390/idr15060069.

Bictegravir/Tenofovir Alafenamide/Emtricitabine: A Real-Life Experience in People Living with HIV (PLWH)

Anna Gidari  1 , Sara Benedetti  1 , Sara Tordi  1 , Anastasia Zoffoli  1 , Debora Altobelli  1 , Elisabetta Schiaroli  1 , Giuseppe Vittorio De Socio  1 , Daniela Francisci  1
Affiliations

Bictegravir/Tenofovir Alafenamide/Emtricitabine: A Real-Life Experience in People Living with HIV (PLWH)

Anna Gidari et al. Infect Dis Rep. .

Abstract

Background: Bictegravir (BIC), a recently introduced integrase inhibitor, is available in a single tablet regimen with tenofovir alafenamide (TAF) and emtricitabine (FTC) (BIC-STR). This study aimed to describe a real-life experience with BIC-STR.

Methods: We retrospectively analyzed the data of people living with HIV (PLWH) on antiretroviral therapy (ART) with BIC-STR followed by the Clinic of Infectious Diseases of Perugia (Perugia, Italy) from September 2019 to February 2023.

Results: 270 PLWH were enrolled with a median follow-up time on BIC-STR of 2.2 years (IQR 1.2-2.7). In the overall population, in treatment-experienced (N = 242), in treatment-naïve (N = 28), and in population with age > 60 years old (N = 86), we observed that CD4 cell count improved in absolute number, percentage and CD4/CD8 ratio, under BIC-STR. Patients with viremia < 50 cp/mL increased in all groups. In the overall population, previous ART with TAF and nadir CD4 cell count favored immunological recovery. In the ART-experienced group, time in therapy with BIC-STR was associated with HIV-RNA undetectability. In the older group, previous opportunistic infection and advanced age were associated with lower CD4 count.

Conclusions: BIC-STR was demonstrated, in real-life, to be a valid option for a switch, such as initial ART.

Keywords: HIV; antiretroviral; bictegravir; integrase inhibitors; real-life.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Patient selection flow-chart.
Figure 2
Figure 2
Multiple logistic regression: variables that influence the reach of target undetected viermia. HIV, human immunodeficiency virus; BIC-STR, cp, copies; bictegravir-single tablet regimen.
Figure 3
Figure 3
Multiple logistic regression: variables that influence a good immunological recovery, defined as CD4 count > 500 cells/mm3, in overall population. TAF, tenofovir alafenamide; cp, copies; HCV, hepatitis C virus; BIC-STR, bictegravir single tablet regimen.
Figure 4
Figure 4
Multiple logistic regression: variables that influence a good immunological recovery (CD4+ T cell count > 500 cells/mm3) in patients older than 60 years old. TAF, tenofovir alafenamide; cp, copies.
See this image and copyright information in PMC

References

    1. Dąbrowska M.M., Wiercińska-Drapało A. Integrase inhibitors as a new class of ARV treatment. HIV AIDS Rev. 2007;6:10–14. doi: 10.1016/S1730-1270(10)60053-7. - DOI
    1. Ryom L., De Miguel R., Cotter A.G., Podlekareva D., Beguelin C., Waalewijn H., Arribas J.R., Mallon P.W.G., Marzolini C., Kirk O., et al. Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021. HIV Med. 2022;23:849–858. doi: 10.1111/hiv.13268. - DOI - PMC - PubMed
    1. Calmy A., Ford N., Hirschel B., Reynolds S.J., Lynen L., Goemaere E., Garcia De La Vega F., Perrin L., Rodriguez W. HIV viral load monitoring in resource-limited regions: Optional or necessary? Clin. Infect. Dis. 2007;44:128–134. doi: 10.1086/510073. - DOI - PubMed
    1. Lagi F., Botta A., Ciccullo A., Picarelli C., Fabbiani M., di Giambenedetto S., Borghi V., Mussini C., Bartoloni A., Sterrantino G. Early discontinuation of DTG/ABC/3TC and BIC/TAF/FTC single-tablet regimens: A real-life multicenter cohort study. HIV Res. Clin. Pract. 2021;22:96–101. - PubMed
    1. Mazzitelli M., Trunfio M., Putaggio C., Sasset L., Leoni D., Lo Menzo S., Mengato D., Cattelan A.M. Viro-Immunological, Clinical Outcomes and Costs of Switching to BIC/TAF/FTC in a Cohort of People Living with HIV: A 48-Week Prospective Analysis. Biomedicines. 2022;10:1823. doi: 10.3390/biomedicines10081823. - DOI - PMC - PubMed